Treatment of dyslipidemia: the problem of reaching the goal

Area of Science:

• Cardiology
• Endocrinology
• Public Health

Background:

• Dyslipidemia significantly contributes to cardiovascular disease (CVD) morbidity and mortality.
• Despite increased awareness, effective treatment of dyslipidemia remains a challenge, with many patients not achieving therapeutic targets.
• A concerning proportion of individuals receiving lipid-lowering treatment fail to meet recommended goals, particularly those with high cardiovascular risk or type 2 diabetes.

Purpose of the Study:

• To evaluate the achievement of low-density lipoprotein (LDL) treatment goals in a large cohort of Chinese individuals receiving lipid-lowering therapy.
• To identify factors contributing to the suboptimal management of dyslipidemia in a real-world setting.

Main Methods:

• Cross-sectional study design.
• Analysis of data from 25,697 Chinese individuals undergoing lipid-lowering treatment.
• Assessment of LDL cholesterol levels in relation to treatment goals.

Main Results:

• Overall, 38.5% of individuals receiving lipid-lowering treatment did not achieve their LDL treatment goal.
• A majority of undertreated patients had high cardiovascular risk and/or type 2 diabetes mellitus.
• Patient compliance and treatment inertia (hesitancy to adjust medication dosage or switch to combination therapy) were identified as key barriers.

Conclusions:

• Suboptimal achievement of LDL treatment goals is prevalent in Chinese individuals, particularly high-risk populations.
• Addressing patient compliance and overcoming physician/patient inertia are crucial for improving dyslipidemia management.
• Novel pharmacological agents and combination therapies offer potential avenues to enhance treatment efficacy.